Explanipedia

Clinical profiles and prognostic impact of residual intravascular and tissue congestion in acute heart failure Open

Daan C H Ceelen, Jozine M. ter Maaten, Geert H.D. Voordes, Gad Cotter, Beth A. Davison , et al. · 2025

Aims Residual congestion (RC) is common at discharge after acute decompensated heart failure (ADHF) and is associated with early mortality and rehospitalization. The prognostic value of distinct RC phenotypes (i.e. intravascular and tissue…

Impact of Mild and Moderate Aortic Stenosis in Acute Heart Failure: Insights From RELAX-AHF-2 Open

Constantijn S. Venema, Marco Metra, Laura Staal, Iris E. Beldhuis, Gad Cotter , et al. · 2025

The presence of mild or moderate aortic stenosis reflects an increased risk profile in patients with acute heart failure, but it is not an independent predictor of poor clinical outcomes.

Current clinical applications of AAV-mediated gene therapy Open

Barry J. Byrne, Kevin M. Flanigan, Susan Matesanz, Richard S. Finkel, Megan A. Waldrop , et al. · 2025

Currently, there are an estimated 8,000 genetic disorders that cumulatively affect approximately 10% of the population. Even among the 5% of patients with genetic disease that have treatment options, these therapeutics rarely address the u…

Physical activity modifies associations between cerebrospinal fluid tau measures and executive function Open

Ryan J. Dougherty, Anja Soldan, Corinne Pettigrew, Barry Greenberg, Adam P. Spira , et al. · 2025

BACKGROUND Alzheimer's disease (AD) is characterized by the abnormal accumulation of amyloid‐beta (Aβ) and tau that can be quantified in vivo through cerebrospinal fluid (CSF) sampling. Physical activity has emerged as a possible modifier …

The relation of eye movements to the occurrence of freezing of gait in Parkinson’s disease Open

Juan Fernández-Ruíz, Heidi C. Riek, Donald C. Brien, Brian C. Coe, David A. Grimes , et al. · 2025

Freezing of gait is a debilitating motor symptom in Parkinson's disease that significantly increases fall risk and impairs quality of life. The poorly understood pathophysiology of freezing of gait presents challenges for early prediction …

White matter tract correlations with spoken language in cerebrovascular disease Open

Dana N Broberg, Seyyed MH Haddad, Katharine Aveni, Alexander Havens, Paula McLaughlin , et al. · 2025

Assessment of spoken language is a promising marker for cognitive impairment in individuals with cerebrovascular disease. However, the underlying neurological basis for spoken language beyond single words and sentences remains poorly defin…

Latest Developments in Gene Therapy for Heart Failure Open

Cameron Andrew Olandt, Cody Kelso, Kimberly N. Hong, Barry Greenberg · 2024

End‐organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure‐2 (RELAX‐AHF‐2) Open

Adriaan A. Voors, Marco Metra, Douwe Postmus, Barry Greenberg, Gad Cotter , et al. · 2024

Aims Serelaxin is recombinant human relaxin‐2, a hormone responsible for haemodynamic adaptations and organ protection in pregnancy. In the RELAX‐AHF trial, serelaxin demonstrated reductions in cardiac, renal and hepatic damage. In RELAX‐A…

PHYSICAL ACTIVITY ATTENUATES THE INFLUENCE OF ALZHEIMER’S BIOMARKERS ON COGNITIVE FUNCTION Open

Ryan J. Dougherty, Anja Soldan, Corinne Pettigrew, Barry Greenberg, Adam P. Spira , et al. · 2024

Alzheimer’s disease (AD) is characterized by the abnormal accumulation of amyloid-β (plaques), and tau (neurofibrillary tangles) that can be quantified in vivo through cerebrospinal fluid (CSF) sampling. Physical activity has emerged as a …

Decongestion and Outcomes in Patients Hospitalized for Acute Heart Failure Open

Matteo Pagnesi, Laura Staal, Jozine M. ter Maaten, Iris E. Beldhuis, Gad Cotter , et al. · 2024

A Randomized-Controlled Trial Targeting Cognition in Early Alzheimer’s Disease by Improving Sleep with Trazodone (REST) Open

Estelle Eyob, Jacob S. Shaw, Arnold Bakker, Cynthia A. Munro, Adam P. Spira , et al. · 2024

Alzheimer’s disease (AD) is a leading cause of mortality and morbidity among aging populations worldwide. Despite arduous research efforts, treatment options for this devastating neurodegenerative disease are limited. Sleep disturbances, t…

Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone—a FIDELITY analysis Open

Bertram Pitt, Rajiv Agarwal, Stefan D. Anker, Peter Rossing, Luís M. Ruilope , et al. · 2024

Aims Hypokalaemia is associated with cardiovascular events and mortality in patients with chronic kidney disease (CKD). This exploratory FIDELITY analysis, a prespecified pooled patient-dataset from FIDELIO-DKD and FIGARO-DKD, investigated…

Clinical characteristics, diagnosis and short‐term outcomes of COVID‐19–associated acute myocarditis in China Open

Huihui Liu, Ping Zhou, Yan Huang, Sulan Yan, Lei Zhou , et al. · 2024

Aims Acute myocarditis (AM) has been recognized as a rare complication of coronavirus disease 2019 (COVID‐19) infection. This study was conducted to present the clinical characteristics, disease courses and short‐term prognoses of Omicron …

Impact of age on clinical outcomes and response to serelaxin in patients with acute heart failure: An analysis from the RELAX‐AHF‐2 trial Open

Riccardo M. Inciardi, Laura Staal, Beth A. Davison, Carlo Lombardi, Douwe Postmus , et al. · 2024

Aims Acute heart failure (AHF) is a major cause of hospitalizations and death in the elderly. However, elderly patients are often underrepresented in randomized clinical trials. We analysed the impact of age on clinical outcomes and respon…

Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer’s Disease Therapeutics Open

Ben Boyarko, Sonia Podvin, Barry Greenberg, Steven E. Arnold, Almudena Maroto Juanes , et al. · 2024

Therapeutic research and development for Alzheimer's disease (AD) has been an area of intense research to alleviate memory loss and neurodegeneration. There is growing interest in drug repositioning and repurposing strategies for FDA-appro…

Distinct Comorbidity Clusters in Patients With Acute Heart Failure Open

Karla Arevalo Gomez, Jasper Tromp, Sylwia M. Figarska, Iris E. Beldhuis, Gad Cotter , et al. · 2024

Comorbidities naturally clustered into 5 mutually exclusive groups in RELAX-AHF-2, showing variations in clinical outcomes. These data emphasize that the specific combination of comorbidities can influence adverse outcomes and treatment re…

Determinants of Guideline-Directed Medical Therapy Implementation During Heart Failure Hospitalization Open

Emily Margolin, Trina Huynh, Alison Brann, Barry Greenberg · 2024

High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial Open

Luca Monzo, Nicolas Girerd, João Pedro Ferreira, Zohra Lamiral, Stefan D. Anker , et al. · 2023

Incidence of Acute Rejection Compared With Endomyocardial Biopsy Complications for Heart Transplant Patients in the Contemporary Era Open

Vincenzo Cusi, Florin Vaida, Nicholas Wettersten, Nicholas Rodgers, Yuko Tada , et al. · 2023

Background. The reference standard of detecting acute rejection (AR) in adult heart transplant (HTx) patients is an endomyocardial biopsy (EMB). The majority of EMBs are performed in asymptomatic patients. However, the incidence of treated…

Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea Open

Eui-Soon Kim, Sun‐Kyeong Park, Jong‐Chan Youn, Hye Sun Lee, Hae‐Young Lee , et al. · 2023

ClinicalTrials.gov Identifier: NCT01389843.

Prescribing anti‐amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions Open

Barry Greenberg, Cynthia A. Lemere, Lisa L. Barnes, Kathleen M. Hayden, Walter A. Kukull , et al. · 2023

The objective of this editorial is to advocate for minoritized individuals, as well as other demographic groups who were under-represented in clinical trials of anti-amyloid immunotherapies, to ensure that they are able to make fully infor…

International Consensus on Differential Diagnosis and Management of Patients With Danon Disease Open

Kimberly N. Hong, Emily Eshraghian, Michael Arad, Alessia Argirò, Michela Brambatti , et al. · 2023

Danon disease is a rare X-linked autophagic vacuolar cardioskeletal myopathy associated with severe heart failure that can be accompanied with extracardiac neurologic, skeletal, and ophthalmologic manifestations. It is caused by loss of fu…

A multi-stem cell basis for craniosynostosis and calvarial mineralization Open

Seoyeon Bok, Alisha R. Yallowitz, Jun Sun, Jason McCormick, Michelle Cung , et al. · 2023

Cerebrospinal Fluid Alzheimer’s Disease Biomarker Patterns of Change Prior to the Onset of Mild Cognitive Impairment Open

Yifei Sun, Abhay Moghekar, Anja Soldan, Corinne Pettigrew, Barry Greenberg , et al. · 2023

Background: Cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD) are altered many years before the onset of clinical symptoms of mild cognitive impairment (MCI). Incorporating clinical symptom onset time into biomarker modeling…

Mortality Prediction in Patients With or Without Heart Failure Using a Machine Learning Model Open

Se Yong Jang, Jin Joo Park, Eric Adler, Emily Eshraghian, Faraz S. Ahmad , et al. · 2023

Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease Open

Ben Boyarko, Sonia Podvin, Barry Greenberg, Jeremiah D. Momper, Yadong Huang , et al. · 2023

Therapeutics discovery and development for Alzheimer’s disease (AD) has been an area of intense research to alleviate memory loss and the underlying pathogenic processes. Recent drug discovery approaches have utilized in silico computation…

Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF Open

Abhinav Sharma, Daniel Caldeira, Amir Razaghizad, Fausto J. Pinto, Dirk J. van Veldhuisen , et al. · 2023

Objectives COMMANDER-HF was a randomised trial comparing rivaroxaban 2.5 mg two times a day to placebo, in addition to antiplatelet therapy, in patients hospitalised for worsening heart failure with coronary artery disease and sinus rhythm…

Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure Open

Iris E. Beldhuis, Kevin Damman, Peter S. Pang, Barry Greenberg, Beth A. Davison , et al. · 2023

Aims Heart failure (HF) guidelines recommend initiation and optimization of guideline‐directed medical therapy, including mineralocorticoid receptor antagonists (MRAs), before hospital discharge. However, scientific evidence for this recom…

Performance of Risk Models to Predict Mortality Risk for Patients with Heart Failure: Evaluation in an Integrated Health System Open

Faraz S. Ahmad, Ted Ling Hu, Eric Adler, Lucia C. Petito, Ramsey M. Wehbe , et al. · 2023

Background Referral of patients with heart failure (HF) who are at high mortality risk for specialist evaluation is recommended. Yet, most tools for identifying such patients are difficult to implement in electronic health record (EHR) sys…

Benefit versus Risk of Endomyocardial Biopsy for Heart Transplant Patients in the Contemporary Era Open

Vincenzo Cusi, Florin Vaida, Nicholas Wettersten, Nicholas Rodgers, Yuko Tada , et al. · 2023

Background The reference standard of detecting acute rejection (AR) in adult heart transplant (HTx) patients is an endomyocardial biopsy (EMB). The majority of EMBs are performed in asymptomatic patients. However, the benefit of diagnosing…

Barry Greenberg YOU? Author Swipe